Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents

Krusiński, Adam; Grzywa-Celińska, Anna; Szewczyk, Katarzyna; Grzycka-Kowalczyk, Luiza; Emeryk-Maksymiuk, Justyna; Milanowski, Janusz

doi:10.1155/2021/6284987

Cited by 6 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association between PTB and inflammatory bowel disease (IBD) was also reported in a recent study. Krusinski et al found that biological agents for IBD may increase the susceptibility to TB [ 29 ]. Additionally, we found that some comorbidities demonstrated age discrepancies.…”

Section: Discussionmentioning

confidence: 99%

Comorbidity increases the risk of pulmonary tuberculosis: a nested case-control study using multi-source big data

Wang,

Song,

Wang

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background Some medical conditions may increase the risk of developing pulmonary tuberculosis (PTB); however, no systematic study on PTB-associated comorbidities and comorbidity clusters has been undertaken. Methods A nested case-control study was conducted from 2013 to 2017 using multi-source big data. We defined cases as patients with incident PTB, and we matched each case with four event-free controls using propensity score matching (PSM). Comorbidities diagnosed prior to PTB were defined with the International Classification of Diseases-10 (ICD-10). The longitudinal relationships between multimorbidity burden and PTB were analyzed using a generalized estimating equation. The associations between PTB and 30 comorbidities were examined using conditional logistic regression, and the comorbidity clusters were identified using network analysis. Results A total of 4265 cases and 17,060 controls were enrolled during the study period. A total of 849 (19.91%) cases and 1141 (6.69%) controls were multimorbid before the index date. Having 1, 2, and ≥ 3 comorbidities was associated with an increased risk of PTB (aOR 2.85–5.16). Fourteen out of thirty comorbidities were significantly associated with PTB (aOR 1.28–7.27), and the associations differed by sex and age. Network analysis identified three major clusters, mainly in the respiratory, circulatory, and endocrine/metabolic systems, in PTB cases. Conclusions Certain comorbidities involving multiple systems may significantly increase the risk of PTB. Enhanced awareness and surveillance of comorbidity are warranted to ensure early prevention and timely control of PTB.

show abstract

Section: Discussionmentioning

confidence: 99%

Comorbidity increases the risk of pulmonary tuberculosis: a nested case-control study using multi-source big data

Wang,

Song,

Wang

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

show abstract

“…While anti-TNF can be used for severe ulcerative colitis treatment, there’s a risk of recurrence if it is discontinued [ 25 ]. Furthermore, biologic agents, exemplified by anti-TNF drugs, introduce an elevated vulnerability to infections among UC patients, concurrently posing risks of diverse tuberculosis manifestations [ 26 , 27 ]. Notwithstanding the reduction in surgical interventions post-biologic usage, the lingering disease susceptibility coupled with postoperative complications remains a persistent concern [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

PVA enema ameliorates DSS-induced acute colitis in mice

Zhang,

Kong,

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Background Ulcerative colitis (UC) represents a clinically challenging condition characterized by persistent damage to the colonic epithelial mucosa as the principal pathological feature. Polyvinyl alcohol (PVA) solution, primarily composed of glue, is a biodegradable polymer material that has found utility in the medical field. This research endeavors to investigate the therapeutic potential of PVA water solution in ameliorating UC in mice. Methods UC was induced in 48 C57BL/6 mice by administering 2.5% DSS in their diet for 6 days. Mice were treated with different concentrations of PVA (0.1 mg/ml PVA, 0.3 mg/ml PVA, 1 mg/ml PVA, 3 mg/ml PVA, 10 mg/ml PVA) enemas (n = 6). Disease Activity Index (DAI) and histologic score were evaluated for inflammation degree. Furthermore, mouse colon organoids were cultured, which were used to assess the effects of PVA on expansion in vitro. Results PVA aqueous solutions (1 mg/ml and 3 mg/ml) were able to alleviate the DAI in mice. By DAY 6, there was a significant 3/5-fold decrease in DAI within the 1 mg/ml PVA group (p = 0.02). Histopathology scores demonstrated improvements, while the levels of inflammatory factors in the intestinal mucosal tissue were reduced. Additionally, it was confirmed that PVA could promote the expansion of colonic organoids in vitro. Conclusions In summary, our investigation has yielded findings indicating that PVA holds the potential to ameliorate symptoms associated with colitis in murine subjects afflicted by DSS-induced colitis, primarily through its facilitation of intestinal stem cell expansion. This study might provide a new candidate for the clinical treatment of ulcerative colitis.

show abstract

“…Long-term use of immunomodulators is not only toxic, but one case follow-up showed possible transformation into high-grade squamous intraepithelial lesions, which are precancerous [25]. Biologics such as anti-TNF drugs not only increase the risk of infection in UC patients, but may also present with various types of TB [26,27]. Although surgical treatment is reduced after the use of biologics, the risk of disease remains high and postoperative complications continue to plague [28].…”

Section: Discussionmentioning

confidence: 99%

PVA enema ameliorates DSS-induced acute colitis in mice

Zhang

Kong

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Polyvinyl alcohol (PVA) solution is a biodegradable polymer material with the main component of glue. PVA can now be used in the medical field. Ulcerative colitis (UC) is a clinically intractable disease with persistent damage to the colonic epithelial mucosa as the main pathological change. The research aims to explore the therapeutic effect of PVA water solution on UC in mice. Methods The UC model was induced by dextran sulfate sodium, and the therapeutic effects of different concentrations of PVA water solution on the model mice were observed. Besides the changes in mouse body weight, clinical disease activity index, and colon length were recorded. Histopathological examination staining and inflammatory factors levels were used to evaluate the degree of colonic tissue damage and inflammation. Furthermore, mouse colon organoids were cultured, which were used to assess the effects of different concentrations of PVA aqueous solution on the number of organoids in vitro. Results We reported that treatment with PVA aqueous solution (1 mg/ml and 3 mg/ml) can significantly alleviate the weight loss of the colitis group, and dramatically improve histopathology scores, meanwhile the levels of inflammatory factors in intestinal mucosal tissue were decreased. It was also confirmed that PVA could greatly increase the number of colonic organoids in vitro. Conclusions In summary, PVA can relieve tissue damage and clinical symptoms of ulcerative colitis. We infer that the underlying mechanism may be related to promoting intestinal stem cell proliferation by PVA, which might in turn promote the repair of intestinal mucosal damage. This study might provide a new candidate for the clinical treatment of ulcerative colitis.

show abstract

Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents

Cited by 6 publications

References 45 publications

Comorbidity increases the risk of pulmonary tuberculosis: a nested case-control study using multi-source big data

Comorbidity increases the risk of pulmonary tuberculosis: a nested case-control study using multi-source big data

PVA enema ameliorates DSS-induced acute colitis in mice

PVA enema ameliorates DSS-induced acute colitis in mice

Contact Info

Product

Resources

About